Totalt antall besøk

Visninger
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis1321

Totalt antall besøk pr måned

september 2023oktober 2023november 2023desember 2023januar 2024februar 2024mars 2024
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis515522208

Nedlastinger av fil

Visninger
article.pdf256

Visninger pr land

Visninger
France526
United States464
Germany73
Sweden48
Norge44
Ireland33
China28
United Kingdom23
Portugal10
Vietnam9

Visninger pr by

Visninger
Ashburn279
Frankfurt am Main40
Ann Arbor33
Dublin33
Southend19
Oslo11
Camarate10
Guangzhou7
Hanoi7
Boardman5